EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Immune Effector Cell-associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)

Jerry C Lee, William T Johnson, Melissa Hines, Nirali N Shah

Hematology/Oncology Clinics of North America · 2025-06 · 39 (3) · 617-643

DOI: 10.1016/j.hoc.2025.02.005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Hematology/Oncology Clinics of North America, 2025-06. Verfasst von Jerry C Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hematology, Blood and Marrow Transplantation, and Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, University of Ca…. Hauptthemen laut MEDLINE: Lymphohistiocytosis, Hemophagocytic, Immunotherapy, Adoptive. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Intramural NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) is a complication of adoptive cell therapy. Presenting with clinical manifestations of hyperinflammation and surrogate indicators of hyperinflammation such as elevations in serum ferritin and hepatic transaminases, decreasing cell counts, and hypofibrinogenemia, IEC-HS resembles primary and other forms of secondary hemophagocytic lymphohistiocytosis. Nonetheless, this is an iatrogenic complication resulting from the induction of hyperinflammatory pathways during T-cell-mediated anticancer targeting. Distinct from cytokine release syndrome, IEC-associated neurotoxicity syndrome, and IEC-associated hematotoxicity, IEC-HS can be life-threatening. Identification of IEC-HS, optimization of treatment strategies, and use of supportive care are critical to improving outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphohistiocytosis, HemophagocyticImmunotherapy, AdoptiveHumans

Stichwörter der Autor:innen

Adoptive cell therapyChimeric antigen receptor T-cell therapyCytokineCytokine release syndromeFerritinHemophagocytic lymphohistiocytosisImmune effector cell

Autor:innen und Institutionen

  • Hematology, Blood and Marrow Transplantation, and Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, University of California, UCSF Box 0345, 400 Parnassus Avenue, San Francisco, CA 94143…
  • Lymphoma Service and Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Division of Critical Care Medicine, Department of Pediatric Medicine, St. Jude Children's Research Hospital, MS #734262 Danny Thomas Place, Memphis, TN 38105, USA.
  • Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), NIH, Bethesda, MD, USA. Electronic address: Nirali.Shah@nih.gov.

Förderung

  • NCI NIH HHS
  • Intramural NIH HHS
  • National Institutes of Health

Zitieren

APA

Lee, J. C., Johnson, W. T., Hines, M., & Shah, N. N. (2025). Immune Effector Cell-associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS). Hematology/Oncology Clinics of North America, 39(3), 617-643. https://doi.org/10.1016/j.hoc.2025.02.005

Vancouver

Lee JC, Johnson WT, Hines M, Shah NN. Immune Effector Cell-associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS). Hematology/Oncology Clinics of North America. 2025;39(3):617-643. doi:10.1016/j.hoc.2025.02.005

BibTeX
@article{Lee2025,
  author = {Lee, Jerry C and Johnson, William T and Hines, Melissa and Shah, Nirali N},
  title = {Immune Effector Cell-associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)},
  journal = {Hematology/Oncology Clinics of North America},
  year = {2025},
  volume = {39},
  number = {3},
  pages = {617--643},
  doi = {10.1016/j.hoc.2025.02.005}
}
Kostenlos starten →